Innovation in EEG Research: Zeto's 2026 Clinical Trial Sponsorship Winners Announced

Zeto's 2026 Clinical Trial Sponsorship Program Winners Announced

Zeto, Inc., a pioneering company in medical technology, has announced the recipients of its 2026 Clinical Trial Sponsorship Program. This initiative supports groundbreaking research aimed at integrating electroencephalogram (EEG) technology into real-world clinical settings. The selected projects exemplify how EEG can be utilized beyond traditional environments to tackle significant challenges in stroke monitoring, delirium assessment, and epilepsy treatment — areas where timely and accurate brain data can significantly affect patient outcomes.

“Research transcends borders, and this year’s selected projects reflect a truly global effort to evolve EEG technologies,” stated Florian Strelzyk, Ph.D., CEO of Zeto. “By overcoming obstacles such as setup duration, patient discomfort, and workflow integration, we can unlock new clinical applications for EEG.”

The three winning projects for 2026 are:

1. Electrocardiography Brain Perfusion Index (EPBi): Led by Prof. Craig Anderson and Dr. Xiaoying Chen from The George Institute for Global Health, Australia, this study focuses on using EBPi as a biomarker to monitor neurological decline in acute ischemic stroke patients. Utilizing Zeto ONE’s comprehensive EEG and synchronized ECG capabilities, this project aims to expand monitoring across various cerebral regions for a more thorough assessment of brain perfusion.

2. Delirium Electroencephalography (EEG) and Phenotyping with Endpoints (DEPEND): Conducted by Dr. Gregory Scott at Imperial College London, UK, this research intends to validate portable EEG systems using Zeto ONE. It aims to develop machine-learning metrics to detect and evaluate delirium, addressing the pressing need for an objective means to identify this underdiagnosed condition effectively.

3. Optimization of Neuromodulation Therapy for Drug-Resistant Epilepsy: Led by Dr. Jonathon J. Parker from Mayo Clinic Arizona, this investigation is set to explore how short-term EEG biomarkers can inform personalized neuromodulation treatments. The goal is to analyze EEG responses captured during routine visits using Zeto ONE to predict how well patients will respond to treatment and to optimize stimulation parameters for better seizure management.

Each winning project will benefit from access to Zeto's EEG systems, innovative gel-free electrodes, seamless connectivity to Zeto’s cloud platform, extensive training, and resources for effective data collection. These clinical trials are slated to commence later this year, marking a significant step forward in medical research and patient care.

Zeto's Clinical Trial Sponsorship Program, now in its third year, has gained incredible traction, attracting a growing array of top-tier research proposals. Anticipation is building for the next round of competition, which will open up in the fall of 2026.

About Zeto, Inc.

Zeto, Inc. is a frontrunner in next-generation neurotechnology, committed to making brain health insights a standard vital sign in healthcare. With its FDA-approved EEG platform, Zeto offers scalable, real-time measurement of brain activity, providing actionable insights that aid clinical decision-making and integrate brain monitoring into everyday healthcare scenarios. The corporate vision includes leveraging its state-of-the-art technology to enhance access to and quality of medical EEG testing, while also supporting biomedical research and clinical trials.

For more information about Zeto and its innovative technologies, visit Zeto, Inc..